due: 20-05-2014 Research NIH PAR-14-092 US Citizen, Permanent Resident, Faculty required
Bioengineering Research Partnerships (BRP) R01
This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing these technologies and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5-10 years.
due: 05-06-2014 Research NIH PA-12-284 Faculty required
Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21]
The purpose of this FOA is to encourage Exploratory/Developmental Bioengineering Research Grants (EBRG) applications which establish the feasibility of technologies, techniques or methods that: 1) explore a unique multidisciplinary approach to a biomedical challenge; 2) are high-risk but have a considerable pay-off; and 3) develop data which can lead to significant future research. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.
due: 05-06-2014 Research NIH PAR-13-137 Faculty required
Bioengineering Research Grants (BRG) (R01)- PAR-13-137
The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach that can increase our understanding of and solve problems in biological, clinical or translational science.
due: 20-06-2014 Research NIH RFA-CA-13-021 Faculty required
NIH- Research Answers to NCI’s Provocative Questions – Group C (R21)- RFA-CA-13-021
List of PQs for this FOA: Group C Each application must address one and only one specific PQ from Group C, exactly as defined in this FOA. PQC1: (Rewritten for 2013) What properties of pre-cancerous lesions or their microenvironment predict the likelihood of progression to malignant disease? PQC2: (Retained from 2012) What molecular or cellular events establish tumor dormancy after treatment and what leads to recurrence? PQC3: (New for 2013) How do variations in tumor-associated immune responses among patients from distinct well-defined populations, such as various racial/ethnic or age groups, contribute to differences in cancer outcomes? PQC4: (New for 2013) What in vivo imaging methods can be developed to portray the "cytotype" of a tumor — defined as the identity, quantity, and location of each of the different cell types that make up a tumor and its microenvironment?
due: 20-06-2014 Research NIH RFA-CA-13-022 Faculty required
NIH- Research Answers to NCI’s Provocative Questions – Group D (R01) – RFA-CA-13-022
List of PQs for this FOA: Group D Each application must address one and only one specific PQ from Group D, exactly as defined in this FOA. PQD1: (Retained from 2012) What molecular properties make some cancers curable with conventional chemotherapy? PQD2: (New for 2013) What features of standard-of-care therapies enhance or inhibit the efficacy of immunotherapy? PQD3: (New for 2013) Do tumors evolve common features that could act as new therapeutic targets when they metastasize to the same secondary site? PQD4: (New for 2013) What are the mechanistic bases for differences in cancer drug metabolism and toxicity at various stages of life?